FTO and acute myeloid leukemia: In addition, we analyzed our m6A-seq data from human AML cells and found that over 95% of the m6A peaks affected by R-2HG treatment or FTO knockdown or overexpression are internal m6A, not 5′ cap m6Am69 (Su et al., unpublished).